Stryker Enters China Race With Trauson Bid

The acquisition of Trauson would give Stryker deep roots into the untapped territories of China’s $1.5 billion orthopedics industry, the so-called second- and third-tier markets in lesser developed areas where multinationals haven’t been able to access.

The race to acquire a local foothold in China’s medical device industry is on. Stryker Corp.’s bid to pay $764 million for a controlling share in Trauson Holdings Company Ltd. would take out China’s second sizable domestic supplier of orthopedic implants.

The acquisition of Trauson would give Stryker deep roots into the untapped territories of China’s $1.5 billion orthopedics industry, the...

More from Archive

More from Medtech Insight